Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 4/20 | 0.42 |
| ▸ | AURKA | O14965 | 2/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.39 |
| ▸ | INCENP | Q9NQS7 | 2/20 | 0.39 |
| ▸ | TPX2 | Q9ULW0 | 2/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | TTK | P33981 | 3/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | HASPIN | Q8TF76 | 4/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20123032 | 0.89 | DYRK1A (0.41) | DYRK1AAURKAAURKBINCENPTPX2 | |
| SCHEMBL20122935 | 0.89 | DYRK1A (0.41) | DYRK1AAURKAAURKBINCENPTPX2 | |
| SCHEMBL29756325 | 0.89 | DYRK1A (0.41) | DYRK1AAURKAAURKBINCENPTPX2 | |
| SCHEMBL30664285 | 0.89 | DYRK1A (0.41) | DYRK1AAURKAAURKBINCENPTPX2 | |
| SCHEMBL22474556 | 0.76 | DYRK1A (0.41) | DYRK1AHASPINDYRK2ACHE | |
| SCHEMBL20122758 | 0.76 | PDK2 (0.42) | DYRK1AHASPINDYRK2 | |
| SCHEMBL20123058 | 0.74 | DYRK1A (0.36) | DYRK1ALRRK2HASPINDYRK2MAOA | |
| SCHEMBL20122936 | 0.74 | AURKA (0.41) | DYRK1AAURKAAURKBINCENPTPX2 | |
| SCHEMBL20122764 | 0.74 | DYRK1A (0.50) | DYRK1AHASPINDYRK2ACHEMAOA | |
| SCHEMBL29756487 | 0.74 | DYRK1A (0.38) | DYRK1AHASPINDYRK2ACHEMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827633-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | SANOFI (FR) | 2023-11-28 | — | — | US | disclosed |
| US-11827633-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | SANOFI (FR) | 2023-11-28 | — | — | US | disclosed |
| US-11130755-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | SANOFI (FR) | 2021-09-28 | — | — | US | disclosed |
| EP-3792262-A1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | SANOFI (FR) | 2021-03-17 | — | — | EP | disclosed |
| EP-3535263-A1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | Sanofi (FR) | 2019-09-11 | — | — | EP | disclosed |
| EP-3318563-A1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | SANOFI (FR) | 2018-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827633-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | COL2A1, IDO1, COL1A1 | DYRK1A 493/4885AURKA 1279/4885AURKB 461/4885 |
| US-11130755-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | COL2A1, IDO1, COL1A1 | DYRK1A 493/4885AURKA 1279/4885AURKB 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.